Actavis’ Avycaz Approval Shows How FDA Handles Limited-Data, Limited-Use Antibiotic

FDA grants approval to two of three indications for gram-negative antibiotic based on Phase II data but follows its advisors in rejecting a third indication that came without human data, offering hints of what the limitations and possibilities of a formal limited population antibiotic approval pathway might look like.